|
WO2021018318A1
|
|
Pharmaceutical composition containing chidamide and surfactant
|
|
WO2021052440A1
|
|
Use of chiglitazar and derivatives thereof in treating type 2 diabetes accompanied by abnormal lipids metabolism
|
|
WO2021037091A1
|
|
Chidamide pharmaceutical composition, preparation method therefor and application thereof
|
|
WO2021037128A1
|
|
Chidamide-containing pharmaceutical composition and use thereof
|
|
WO2021027912A1
|
|
Chidamide-containing anti-tumor pharmaceutical composition and use thereof
|
|
WO2021018226A1
|
|
Heterocyclic compound and application thereof
|
|
CN111759838A
|
|
Pharmaceutical composition of pharmaceutically acceptable salt of sitagliptin and application thereof
|
|
CN111909137A
|
|
Pyridazinone derivative and application thereof
|
|
CN111437393A
|
|
Combined medicine for treating diabetes and complications thereof and pharmaceutical composition thereof
|
|
CN111297866A
|
|
Pharmaceutical composition containing JAK3/JAK1/TBK1 inhibitor and methotrexate and application thereof
|
|
TW202035700A
|
|
Use of kdm5a gene and atrx gene
|
|
TW202034919A
|
|
Use of chiauranib in treating small cell lung cancer
|
|
CN111228264A
|
|
Application of combination of Sidapamide and CGB and autologous hematopoietic stem cells and combination drug
|
|
WO2020103778A1
|
|
Application of chidamide
|
|
CN111195250A
|
|
Application of combination of cydapamide and DICE and combined medicine
|
|
CN110950842A
|
|
Quinoline derivatives having indoleamine-2, 3-dioxygenase inhibitory activity
|
|
WO2020063463A1
|
|
Application of chiglitazar and related compounds thereof
|
|
WO2020034916A1
|
|
Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof
|
|
CN110872275A
|
|
Biphenyl compounds as immunomodulators and uses thereof
|
|
BR112020021664A2
|
|
formamide compound, method of preparation and application of the same
|
